home.social

#hematology — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #hematology, aggregated by home.social.

  1. Hemodialysis patients with blood type A exhibit significantly lower risks of both all-cause and cardiovascular mortality compared to those with other blood types. This finding directly contrasts with the general population, where blood type O is typically associated with the lowest risk of cardiovascular disease.
    #Nephrology #Cardiology #Hematology #Epidemiology #sflorg
    sflorg.com/2026/07/med07212601

  2. Hemodialysis patients with blood type A exhibit significantly lower risks of both all-cause and cardiovascular mortality compared to those with other blood types. This finding directly contrasts with the general population, where blood type O is typically associated with the lowest risk of cardiovascular disease.
    #Nephrology #Cardiology #Hematology #Epidemiology #sflorg
    sflorg.com/2026/07/med07212601

  3. Hemodialysis patients with blood type A exhibit significantly lower risks of both all-cause and cardiovascular mortality compared to those with other blood types. This finding directly contrasts with the general population, where blood type O is typically associated with the lowest risk of cardiovascular disease.
    #Nephrology #Cardiology #Hematology #Epidemiology #sflorg
    sflorg.com/2026/07/med07212601

  4. Hemodialysis patients with blood type A exhibit significantly lower risks of both all-cause and cardiovascular mortality compared to those with other blood types. This finding directly contrasts with the general population, where blood type O is typically associated with the lowest risk of cardiovascular disease.
    #Nephrology #Cardiology #Hematology #Epidemiology #sflorg
    sflorg.com/2026/07/med07212601

  5. Hemodialysis patients with blood type A exhibit significantly lower risks of both all-cause and cardiovascular mortality compared to those with other blood types. This finding directly contrasts with the general population, where blood type O is typically associated with the lowest risk of cardiovascular disease.
    #Nephrology #Cardiology #Hematology #Epidemiology #sflorg
    sflorg.com/2026/07/med07212601

  6. Researchers have successfully generated red blood cell-like cells capable of producing hemoglobin by utilizing canine induced pluripotent stem cells (iPSCs).
    #VeterinaryMedicine #StemCellBiology #Genetics #Hematology #sflorg
    sflorg.com/2026/07/vet07202601

  7. Researchers have successfully generated red blood cell-like cells capable of producing hemoglobin by utilizing canine induced pluripotent stem cells (iPSCs).
    #VeterinaryMedicine #StemCellBiology #Genetics #Hematology #sflorg
    sflorg.com/2026/07/vet07202601

  8. US FDA Approves Sanofi’s Wearable Injector Form of Blood Cancer Drug

    The U.S. Food and Drug Administration has approved a wearable injector formulation of Sanofi’s blood cancer drug Sarclisa,…
    #France #FR #Europe #EU #Sanofi #bloodcancer #cancercareinnovation #FDAapproval #hematology #infusiontimereduction #multiplemyeloma #on-bodyinjector #Oncology #Sarclisa #SarclisaEscena #subcutaneousdelivery #wearableinjector
    europesays.com/france/50500/

  9. Acute myeloid leukemia (AML) is driven not only by gene mutations but also by its epigenome—specifically, the chromatin state that dictates which genes are active. By mapping these accessible genome regions, researchers have established a new framework that classifies AML into sixteen distinct epigenetic subgroups.
    #Oncology #Epigenomics #MolecularBiology #Hematology #sflorg
    sflorg.com/2026/07/ongy0709260

  10. Acute myeloid leukemia (AML) is driven not only by gene mutations but also by its epigenome—specifically, the chromatin state that dictates which genes are active. By mapping these accessible genome regions, researchers have established a new framework that classifies AML into sixteen distinct epigenetic subgroups.
    #Oncology #Epigenomics #MolecularBiology #Hematology #sflorg
    sflorg.com/2026/07/ongy0709260

  11. europesays.com/ch/69491/ Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA #Advances #and #ASCO #at #breast #cancer #data #EHA #hematology #in #Innovation #Leadership #new #Novartis #prostate) #reinforces #RLT #With

  12. Higher ferritin threshold could detect childhood iron deficiency much earlier

    Many cases of iron deficiency in school-aged children could be diagnosed earlier, according to a new study published…
    #NewsBeep #News #Health #Anemia #AU #Australia #Blood #Cell #Children #Fatigue #hematology #Hemoglobin #irondeficiency #Menstruation #Nutrition #Obesity #physicalactivity #protein #RedBloodCells
    newsbeep.com/au/683335/

  13. A one-time intravenous infusion of ferric carboxymaltose is a highly effective treatment for iron deficiency anaemia during pregnancy. It rapidly and efficiently restores iron levels compared to traditional daily oral supplements.
    #Obstetrics #Gynaecology #PublicHealth #Hematology #sflorg
    sflorg.com/2026/05/med05042601

  14. A one-time intravenous infusion of ferric carboxymaltose is a highly effective treatment for iron deficiency anaemia during pregnancy. It rapidly and efficiently restores iron levels compared to traditional daily oral supplements.
    #Obstetrics #Gynaecology #PublicHealth #Hematology #sflorg
    sflorg.com/2026/05/med05042601

  15. PEAK QESTIONABLE COMPLIMENT

    Yesterday, it emerged that, under ordinary circumstances, MGUS is not followed up with anything like the enthusiasm applied to mine. This is, I was informed – once again – because I am “medically fascinating.”

    I ventured to suggest that such fascination might perhaps merit a thorough inspection of my immune system. I can't help but feel that when fascination is involved, there may be scope for a little extra curiosity.

    Alas, no. The region has resolved that no one is to be investigated for SID.

    (For the record: PID and SID are, in essence, the same affair, except that one arrives at birth. Which is the only version considered deserving of serious investigation and treatment. Apparently.)

    And so matters rest. World-class Swedish healthcare, ladies and gentlemen.

    #healthcare #mgus #hematology #QuestionableCompliment
    #MedicallyFascinating #SecondaryImmunodeficiency

  16. PEAK QESTIONABLE COMPLIMENT

    Yesterday, it emerged that, under ordinary circumstances, MGUS is not followed up with anything like the enthusiasm applied to mine. This is, I was informed – once again – because I am “medically fascinating.”

    I ventured to suggest that such fascination might perhaps merit a thorough inspection of my immune system. I can't help but feel that when fascination is involved, there may be scope for a little extra curiosity.

    Alas, no. The region has resolved that no one is to be investigated for SID.

    (For the record: PID and SID are, in essence, the same affair, except that one arrives at birth. Which is the only version considered deserving of serious investigation and treatment. Apparently.)

    And so matters rest. World-class Swedish healthcare, ladies and gentlemen.

    #healthcare #mgus #hematology #QuestionableCompliment
    #MedicallyFascinating #SecondaryImmunodeficiency

  17. #Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: biotech.industryexaminer.com/a #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews

  18. #Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: biotech.industryexaminer.com/a #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews

  19. #Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: biotech.industryexaminer.com/a #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews

  20. #Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: biotech.industryexaminer.com/a #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews

  21. alojapan.com/1314235/comparabl Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net #AcuteMyeloidLeukaemia #Biomedicine #CancerResearch #general #Hematology #Hokkaido #HokkaidoNews #news #oncology #RiskFactors #北海道 Acute myeloid leukemia (AML) has a median age at diagnosis of 68 years, and many patients are deemed ineligible for…

  22. I'm getting super excited to receive this condenser which is 100% matched to the #Leitz #Dialux 20/EB Universal Condenser.

    Apparently, these Leitz high numerical aperture (na) condensers are like rocking horse nitrogenous compound. I managed to find this one on...

    read more: micronicle.org/f/leitz-apl-oel

    #Science #Microscopy #Technology #Biology #Hematology #Haematology

  23. Postdoc fellow in hematology

    Fox Chase Cancer Center

    The Luo lab in the Fox Chase Cancer Center @CEI-FCCC is hiring! Interested in stem cell fate regulation and RNA biology? Please join us!

    See the full job description on jobRxiv: jobrxiv.org/job/fox-chase-canc

    #hematology #hematopoiesis #Leukemia_Modeling. #RNA #rna_biology ...
    jobrxiv.org/job/fox-chase-canc

  24. Postdoc fellow in hematology

    Fox Chase Cancer Center

    The Luo lab in the Fox Chase Cancer Center @CEI-FCCC is hiring! Interested in stem cell fate regulation and RNA biology? Please join us!

    See the full job description on jobRxiv: jobrxiv.org/job/fox-chase-canc

    #hematology #hematopoiesis #Leukemia_Modeling. #RNA #rna_biology ...
    jobrxiv.org/job/fox-chase-canc